At a glance
IOP LOWERING EFFECT OF TRAVOPROST IN NORMAL-TENSION GLAUCOMA
Newly diagnosed NTG patients were randomised to either once daily topical travoprost 0.004% (54, treatment group) or no treatment (34, control group). The average, maximum, and minimum diurnal IOPs for treated patients were statistically significantly lower than for controls. When compared with baseline IOP, the treatment group demonstrated a decrease of 16.1%, 13.5% and 16.7% in the average IOP, maximum IOP, and minimum IOP, respectively. Of those treated, about one third achieved decrease in average IOP of at least 20%; only about one tenth achieved a reduction of at least 30%. Ang et al conclude that travoprost monotherapy is unable to produce the desirable 30% reduction in average IOP.
See page 1129
BRITISH OCULOPLASTIC SURGERY SOCIETY: NATIONAL PTOSIS SURVEY
In an effort to assess the results of primary aponeurotic ptosis surgery among UK ophthalmic oculoplastic surgeons, Scoppettuolo et al conducted a prospective, web-based, non-comparative, interventional study. 40 consultant-led teams from 27 units across the UK participated in the study. Surgical results were assessed …